TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: ED50 and ED95 values of isobaric bupivacaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of hypotension during surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Experiential learning effectiveness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: contrast ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contrast-Induced Nephropathy (CIN) occurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Plasma DHA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Erythrocyte DHA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rectal DHA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total stain score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stain area reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stain intensity reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival as a prognostic factor
Endpoint domain: Mortality/survival
Primary endpoint: Self-care ability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Compliance
Endpoint domain: Life impact
Endpoint subdomain: Other resource use
Primary endpoint: Chest compressions per minute
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of correct landmark for chest compression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean plasma levels of ss‐carotene and total carotenoids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rates of hippocampal atrophy (%/year)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: linear dimensions reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of cocaine dependence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Auscultation grading of intravenous injections
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete resolution of middle ear effusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in tympanometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DL(CO) change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Willingness to consider participation in a clinical trial
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Aqueous Humor Formation (AHF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Reduction in tingling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in numbness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5-year cumulative incidence of MACE
Endpoint domain: Mortality/survival
Primary endpoint: 5-year rates of cardiac death
Endpoint domain: Mortality/survival
Primary endpoint: 5-year rates of recurrent MI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in agoraphobic avoidance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in panic attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean intragastric pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean % time pH>3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean % time pH>4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean duration of inability to work
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Pain reduction at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent EI compensation at the test meal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fagerström Test of Nicotine Dependence scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alcohol Dependence Scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: medical admissions per day
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: non-medical admissions per day
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: transfers to other hospitals per day
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: percentage of good clinical response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean wear proportion of adjustable glasses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Best-corrected visual acuity with adjustable glasses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life increase
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: 30-min step count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PME/PDE levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tCho levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC PPG0030‐0430 h reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-h heart rate change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Aneurysm rupture rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Disability rate (mRS 3-6)
Endpoint domain: Adverse events/effects
Primary endpoint: Cost difference
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Improvement in disease severity (APACHE II scores)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spatial cognition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Tolerability of metformin XR
Endpoint domain: Adverse events/effects
Primary endpoint: ACR 20% improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean disease activity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Erythrocyte sedimentation rate and C-reactive protein values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: oxazepam dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 12-month amputation-/revision-free survival
Endpoint domain: Mortality/survival
Primary endpoint: failure resulting in repeat graft revision, graft occlusion, or major amputation
Endpoint domain: Mortality/survival
Primary endpoint: Total back pain improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MFI general fatigue improvement
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: BSM remodeling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: occurrence of asthma exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum 25OHD levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimum alveolar concentration of sevoflurane
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parent's satisfaction scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Control of any AF/atrial tachycardia off drugs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Recurrence rate of atrial tachycardia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Postoperative myocardial infarctions
Endpoint domain: Adverse events/effects
Primary endpoint: Pain control (visual analogue scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of postoperative PVR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reoperation rate resulting from PVR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: postoperative surgical complications rate
Endpoint domain: Adverse events/effects
Primary endpoint: mean overall hospital stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Fasting endogenous glucose turnover
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Frequency of Factor V Leiden mutation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Frequency of beta-fibrinogen 448 A allele
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Frequency of prothrombin variant G20210A
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean serum IGF-1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean final visual acuity (logMAR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Screening detection of cancers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Satisfactory sedation ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: forced expiratory flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: expiratory reserve volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rate of RD (Respiratory Depression)
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement or resolution of cough
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serious clotting events
Endpoint domain: Adverse events/effects
Primary endpoint: Median circuit survival time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of CBV events
Endpoint domain: Mortality/survival
Primary endpoint: Mortality for hemorrhagic stroke
Endpoint domain: Mortality/survival
Primary endpoint: Mortality for ischemic stroke
Endpoint domain: Mortality/survival
Primary endpoint: Mean visual analog pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Readmission to the hospital for unremitting pain
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Risk of high-grade tumors
Endpoint domain: Mortality/survival
Primary endpoint: Posterior capsule opacification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Anterior capsulorhexis diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: IOL decentring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: 3 h-TEF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: First- and second-phase insulin response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: hip bone mineral density increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative International Index of Erectile Function‐5 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of potent patients 6 months after prostatectomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achieving intercourse by vaginal penetration without a phosphodiesterase 5 inhibitor
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: composite of death or nonfatal myocardial infarction, hospitalization for unstable angina, heart failure or peripheral vascular event
Endpoint domain: Mortality/survival
Primary endpoint: CLABSI rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Activation markers of nasal inflammatory cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Platelet yield
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Maximal aggregation of platelets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Concentration of soluble p-selectin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: relief from atypical depressive symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in general mental health
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: improvement in social functioning
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Decrease in number of hot flashes (HFs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stair climb power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chair stand time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systolic Blood Pressure (BP) increase during exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diastolic Blood Pressure (BP) increase during exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time interval before the onset of Raynaud's phenomenon
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Digital systolic blood pressures in cold temperatures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mallampati score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Soft tissue injuries
Endpoint domain: Adverse events/effects
Primary endpoint: overall scar area reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adverse events associated with treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Rates of normal menstruation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Acne scar severity index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Qualitative scarring grading system
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: ASAE volume consumed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hourly blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: International normalized ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: treadmill walking time to onset of claudication pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perception of health-related QOL
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adequate relief
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean plasma lersivirine AUC24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lersivirine C24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Atazanavir Ctrough
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: wound disruptions requiring intervention
Endpoint domain: Adverse events/effects
Primary endpoint: AUC0‐72h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CCmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevention of shivering post spinal anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Injection and removal time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Residual emulsification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insulin Resistance (IR) variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: biochemical failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: any failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of variceal bleeding (FVB)
Endpoint domain: Mortality/survival
Primary endpoint: Lipid bioaccessibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Short Form Health Survey quality-of-life scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: total catheter burden score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of attacks responding within 4 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CGI-C improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: All-cause discontinuation rates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Histamine wheal and flare response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Allergen wheal and flare response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: TMJ pain reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximal mouth opening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lateral movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum triglyceride reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Exclusive breastfeeding rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infant's birth weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infant's head circumference-for-age z-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 180-day cumulative incidences of grade II-IV acute GVHD
Endpoint domain: Adverse events/effects
Primary endpoint: ADR scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Glycated insulin response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Plasma glucose response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: ED(50) of propofol for LMA insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: improvements in verbal working memory storage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvements in nonverbal working memory storage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean HbA1c after 16 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of confirmed hypoglycaemia
Endpoint domain: Adverse events/effects
Primary endpoint: Coronary artery patency (TIMI grade 3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Self-care confidence score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Consent to donate organs
Endpoint domain: Mortality/survival
Primary endpoint: Donation discussions with provider
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Satisfaction with time spent with provider
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Muscle Function Scale (MFS) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Virologic response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Forearm blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Insulinaemia levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: degree of amnesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: psychological measures
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 60-second all-out exercise performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk for primary SPRINT outcome
Endpoint domain: Mortality/survival
Primary endpoint: Cumulative SBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Development of SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: serum aldosterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: urine aldosterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: SD of glucose values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mean amplitude of glycemic excursion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pathological Complete Response (pCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Vibriocidal antibody responses to V. cholerae O1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes